Research Article

Research Progress on Multiple Effects and Clinical Application of Proprotein Convertase Subtilisin-kexin9 Inhibitors

Authors

  • Yan Feng Shaanxi University of Traditional Chinese Medicine;Department of Cardiovascular Medicine, The Second Affiliated Hospital of Air Force Medical University
  • Weng-Ping Luo Shaanxi University of Traditional Chinese Medicine
  • Ming-Ming Zhang Department of Cardiovascular Medicine, The Second Affiliated Hospital of Air Force Medical University
  • Lin-Cong She Department of Cardiovascular Medicine, The Second Affiliated Hospital of Air Force Medical University
  • Jia-Xin Wang Department of Cardiovascular Medicine, The Second Affiliated Hospital of Air Force Medical University
  • Yong-Xin Sun Department of Cardiovascular Medicine, The Second Affiliated Hospital of Air Force Medical University
  • Hao-Qing Chen Department of Cardiovascular Medicine, The Second Affiliated Hospital of Air Force Medical University
  • Wei Zhang Department of Cardiovascular Medicine, The Second Affiliated Hospital of Air Force Medical University

Abstract

PCSK9 inhibitors (Proprotein convertase subtilisin-kexin9 inhibitors) not only have a good lipid-lowering effect but also have the effects of improving cardiovascular outcome, anti-inflammation, reducing oxidative stress and improving vascular endothelium. In recent years, the continuous research and development of PCSK9 inhibitors have provided new ideas for the treatment of cardiovascular diseases. This article reviews the multiple action mechanisms of PCSK9 inhibitors and their research in kidney disease and cerebrovascular diseases.

Article information

Journal

Journal of Medical and Health Studies

Volume (Issue)

5 (2)

Pages

54-58

Published

2024-04-24

How to Cite

Feng, Y., Luo, W.-P., Zhang, M.-M., She, L.-C., Wang, J.-X., Sun, Y.-X., Chen, C., & Zhang, W. (2024). Research Progress on Multiple Effects and Clinical Application of Proprotein Convertase Subtilisin-kexin9 Inhibitors. Journal of Medical and Health Studies, 5(2), 54–58. https://doi.org/10.32996/jmhs.2024.5.2.6

Downloads

Keywords:

Proprotein convertase subtilisin-kexin9 inhibitor, Vascular endothelium, Pleiotropy, Blood lipids, Cardiovascular outcomes, Inflammation, Oxidative stress, Cerebrovascular disease, Kidney disease